Anthropic Establishes Physical Biology Lab for AI Drug Discovery

Artificial intelligence startup Anthropic has established a dedicated biology laboratory in the San Francisco Bay Area, transitioning its scientific ambitions from digital text generation into physical wet-lab experimentation. The facility allows researchers to generate proprietary biological data, perform high-throughput experiments, and validate machine learning outputs in real time rather than relying entirely on public datasets and external academic partnerships.

The development marks a strategic push into AI-driven drug discovery for the creator of the Claude assistant family. By building physical lab infrastructure, Anthropic aims to create tighter feedback loops where algorithmic predictions can be tested directly at the bench and experimental results can be fed back immediately to refine model precision.

According to Eric Kauderer-Abrams, Anthropic's head of life sciences, physical experimentation remains an essential final test for biological research. In an interview, Kauderer-Abrams explained that the company operates in a manner typical of traditional biotechnology firms, combining in-house wet-lab capabilities with external partner collaborations.

Anthropic intends to focus its preclinical work on neglected therapeutic areas and conditions previously considered undruggable, such as complex bispecific and trispecific antibodies that target multiple points on a cell. The company has stated that it will stop short of conducting human clinical trials, establishing a clear boundary to avoid direct commercial competition with traditional pharmaceutical companies that handle late-stage drug development.

Alongside physical lab operations, Anthropic is exploring ways for its Claude models to direct robotic units to carry out automated science experiments with minimal human intervention. The startup recently launched software tools including Claude Science and the Model Hardware Standard, which assists artificial intelligence systems in operating physical laboratory equipment.

The initiative builds upon a broader corporate expansion that includes the acquisition of Coefficient Bio for approximately $400 million in stock and the addition of Novartis CEO Vas Narasimhan to Anthropic's board. Life sciences has emerged as one of the firm's largest investment areas by headcount and resources as the company prepares for a potential public offering.

Anthropic's move into physical biology coincides with heightened industry scrutiny regarding autonomous agent capabilities and biosecurity risks. Company executives have recently highlighted concerns regarding autonomous systems and potential alignment failures in sensitive domains such as biological research.

Despite these safety concerns, Anthropic provides AI services, cloud tools, and software infrastructure to major global drug developers, including Roche subsidiary Genentech, Bristol Myers Squibb, and Novo Nordisk. However, industry observers note that the company faces trust challenges from pharmaceutical partners who require strict data partitioning to ensure proprietary drug programs remain isolated from competing workflows.